Table of Contents

Abstract……. ii

Acknowledgments……. iii

Table of contents……... iv

List of figures…… vii

List of tables and charts……... ix

1. Overview of microtubule interactive agents……... 1

1.1 Introduction to tubulin and microtubules…….. 1

1.2 Tubulin binding agents…….. 6

1.3 Dissertation overview…… 17

References……... 18

2. Introduction to paclitaxel and docetaxel……..... 24

2.1 Discovery and history…… 24

2.2 Bioactivity……. 26

2.3 Structure-activity relationships (SAR)…….. 29

2.4 Synthesis…… 34

2.5 Summary…… 49

References……... 49

3. Androgen-receptor-targeted paclitaxel and docetaxel analogs for treatment of hormone refractory prostate cancer (HRPC)……. 60

3.1 Overview of prostate cancer…….. 60

3.2 Design, synthesis and biological evaluation of androgen-receptor-targeted paclitaxel and docetaxel analogs……. 64

3.3 Conclusions……... 79

3.4 Experimental section……. 80

References……... 114

4. The Biology and Chemistry of Discodermolide……. 121

4.1 Introduction……... 121

4.2 Bioactivity……. 123

4.3 Structure-activity relationships (SAR)…….. 131

4.4 Total Synthesis……... 135

4.5 Summary…… 155

References……... 156

5. Design, synthesis and biological evaluation of simplified and fluorescently labeled discodermolide analogs…….... 167

5.1 Introduction……... 167

5.2 Design and synthesis of fluorescently labeled discodermolide analogs…… 168

5.3 Biological evaluations of the simplified fluorescently labeled discodermolide analog ……..... 180

5.4 Experimental section……. 181

References……... 210

6. Bridged discodermolide analog for conformational study……... 213

6.1 Design of conformationally constrained discodermolide analogs……..... 213

6.2 Synthesis of the bridged analog……..... 215

6.3 Future work…… 221

6.4 Experimental section……. 222

References……... 239

7. Conclusion……. 241

Appendix……..... 243